Omnicell, Inc. (NASDAQ:OMCL) EVP Robin Gene Seim sold 15,109 shares of the stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $50.86, for a total value of $768,443.74. Following the completion of the transaction, the executive vice president now directly owns 58,144 shares in the company, valued at $2,957,203.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Omnicell, Inc. (NASDAQ:OMCL) opened at 49.55 on Friday. Omnicell, Inc. has a 52 week low of $30.35 and a 52 week high of $51.97. The stock’s market cap is $1.86 billion. The stock has a 50 day moving average price of $46.29 and a 200-day moving average price of $41.70.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.02. The firm had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.38 EPS. Equities analysts predict that Omnicell, Inc. will post $1.31 EPS for the current fiscal year.
A number of research analysts have recently weighed in on the company. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. CIBC increased their price objective on Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a report on Wednesday, April 26th. BidaskClub lowered Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. TheStreet lowered Omnicell from a “b-” rating to a “c+” rating in a report on Thursday, May 4th. Finally, Piper Jaffray Companies lowered Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price objective on the stock. in a report on Friday, April 21st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $49.00.
A number of institutional investors have recently modified their holdings of OMCL. Pinebridge Investments L.P. boosted its position in shares of Omnicell by 1.6% in the second quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock valued at $211,000 after buying an additional 76 shares during the period. Arizona State Retirement System boosted its position in shares of Omnicell by 0.5% in the second quarter. Arizona State Retirement System now owns 19,384 shares of the company’s stock valued at $835,000 after buying an additional 100 shares during the period. Monroe Bank & Trust MI boosted its position in shares of Omnicell by 0.3% in the first quarter. Monroe Bank & Trust MI now owns 34,831 shares of the company’s stock valued at $1,416,000 after buying an additional 116 shares during the period. State of Alaska Department of Revenue boosted its position in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares during the period. Finally, 1st Global Advisors Inc. boosted its position in shares of Omnicell by 1.5% in the second quarter. 1st Global Advisors Inc. now owns 7,948 shares of the company’s stock valued at $343,000 after buying an additional 120 shares during the period. Hedge funds and other institutional investors own 96.35% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
